Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine.
Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Duckett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ.
Basu A, et al. Among authors: forsyth pa.
Cancer Immunol Res. 2022 Jan;10(1):108-125. doi: 10.1158/2326-6066.CIR-21-0454. Epub 2021 Nov 16.
Cancer Immunol Res. 2022.
PMID: 34785506
Free PMC article.